Azanta at the European Cancer Congress 2013

2013-08-26

Hellerup, Denmark; August 26, 2013 - Azanta A/S announced today it will attend the European Cancer Congress 2013 in Amsterdam September 27, 2013.

 

About Azanta A/S

Azanta is a privately owned specialty pharma company primarily operating within oncology, women´s health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets or makes available a string of specialty pharma products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. In addition, Azanta A/S has a portfolio of low risk development projects for commercialization within the near future.

For further information, visit www.azanta.com.

 

This press release contains forward looking statements. The words "believe", "expect", "anticipate",  "intend"  and  "plan"  and  similar  expressions  identify  forward  looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage  growth,  the  competitive  environment  in  relation  to  our  business  area  and markets,  our  inability  to  attract  and  retain  suitably  qualified  personnel,  the unenforceability  or  lack  of  protection  of  our  patents  and  proprietary  rights,  our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Azanta is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.  

 

Contact Azanta:

Claus Møller

Azanta A/S, Gearhalsvej 1, DK-2500 Valby, Denmark, Phone +45 7025 9545, Fax: +45 7025 9546, Mail: info@azanta.com

DisclaimerAll rights reserved ©